Robert Haddad
Overview
Explore the profile of Robert Haddad including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
77
Citations
5485
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McCoon P, Wang Y, Lai Z, Zhang Q, Li W, Wildsmith S, et al.
Clin Cancer Res
. 2025 Mar;
PMID: 40080442
Purpose: Understanding the mutational landscape of recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) is important in identifying biomarkers to determine which patients may benefit from immune checkpoint inhibitors...
2.
Haddad R, Fayette J, Teixeira M, Prabhash K, Mesia R, Kawecki A, et al.
JAMA
. 2025 Mar;
PMID: 40079944
Importance: Treating locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) involves any combination of surgery, radiation, and chemotherapy, followed by routine monitoring for local recurrence or...
3.
Luke J, Pinato D, Juric D, LoRusso P, Hosein P, Desai A, et al.
J Immunother Cancer
. 2025 Feb;
13(2).
PMID: 39979069
E7766 is a novel stimulator of interferon genes (STING) agonist, capable of potent activation of immune cells and generating strong antitumor response in preclinical murine tumor models. Here we present...
4.
Sehgal K, Serritella A, Liu M, ONeill A, Nangia C, Pappa T, et al.
J Clin Endocrinol Metab
. 2024 Jun;
PMID: 38943664
Background: There are limited therapeutic options for patients with recurrent/metastatic anaplastic thyroid carcinoma (ATC), and radioiodine refractory (RAIR) differentiated thyroid carcinoma (DTC) refractory to multi-kinase inhibitors. This multi-center trial evaluated...
5.
Lee M, Zhang Z, Sehgal K, Butler R, Stolrow H, Ramush G, et al.
Epigenomics
. 2024 Jun;
16(11-12):799-807.
PMID: 38869472
This study addresses the challenge of predicting the response of head and neck squamous cell carcinoma (HNSCC) patients to immunotherapy. Using DNA methylation cytometry, we analyzed the immune profiles of...
6.
Dennis M, Haddad R
Cancer Cell
. 2024 Feb;
42(3):333-334.
PMID: 38402611
Advances in imaging and novel treatment approaches might have outpaced the prognostic capabilities of the current AJCC/UICC TNM 8 edition for staging nasopharyngeal carcinoma (NPC). In this issue of Cancer...
7.
Ferris R, Mehanna H, Schoenfeld J, Tahara M, Yom S, Haddad R, et al.
Future Oncol
. 2024 Jan;
20(12):739-748.
PMID: 38197296
There is a significant unmet need and lack of treatment options for patients with resected, high-risk, cisplatin-ineligible locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). Xevinapant,...
8.
9.
Reed E, Jankowski S, Spinella A, Noonan V, Haddad R, Nomoto K, et al.
Transl Res
. 2023 Jun;
260:46-60.
PMID: 37353110
Head and neck cancers, which include oral squamous cell carcinoma (OSCC) as a major subsite, exhibit cellular plasticity that includes features of an epithelial-mesenchymal transition (EMT), referred to as partial-EMT...
10.
Diagnosis and Management of Tropomyosin Receptor Kinase Fusion-Positive Thyroid Carcinomas: A Review
Haddad R, Elisei R, Hoff A, Liu Z, Pitoia F, Pruneri G, et al.
JAMA Oncol
. 2023 Jun;
9(8):1132-1141.
PMID: 37289450
Importance: Thyroid epithelial malignant neoplasms include differentiated thyroid carcinomas (papillary, follicular, and oncocytic), follicular-derived high-grade thyroid carcinomas, and anaplastic and medullary thyroid carcinomas, with additional rarer subtypes. The discovery of...